Articles by University of Texas MD Anderson Cancer Center

Phase 2 trial finds durvalumab–ceralasertib boosted immune response and improved outcomes in patients with lung cancer

Phase 2 trial suggests pre-surgical immunotherapy is safe and may be an effective option for patients with soft-tissue sarcomas

Cervical cancer-associated mortality rates continue to spike despite the consistent prevention efforts

Researchers identified characteristics of donated cord blood units associated with strong clinical responses in the Phase 1/2 trial

Results showed a 32 percent lower chance of cancer recurrence, progression, or death with immunotherapy plus chemotherapy versus chemotherapy alone

Translational findings and higher major pathological response support combinations over monotherapy before surgery

The study offers deeper understanding of gastric cancer progression and identifies potential therapeutic target

Novel renal cell carcinoma model may help predict whether tumors have genomic potential to become aggressive

Per the research, precursor states followed a linear evolution pattern, while advanced multiple myeloma displayed a branching pattern

Study validates the safety of combined delivery of engineered virus with immunotherapy to improve survival rate and quality of life in patients

Concurrent intrathecal and intravenous treatment is safe and improves outcomes in a subset of patients with melanoma

This is the first randomized study to report on the role of combination checkpoint inhibitors for early stage NSCLC

Based on gene expression, researchers identified potential therapeutic targets for each subtype

Called CopyKAT, the computational tool enables researchers to gain new insights when analyzing solid tumor samples